文献速递免疫规划妇幼与学校卫生传染病防控与疫情报告

埃塞俄比亚出生剂量乙型肝炎疫苗联合或不联合乙型肝炎免疫球蛋白预防乙型肝炎病毒母婴传播的前瞻性多中心研究

A prospective, multicenter study of hepatitis B birth-dose vaccine with or without hepatitis B immunoglobulin in preventing mother-to-child transmission of hepatitis B virus in Ethiopia.
PubMed 文献 · Vaccine · 2024-10-19

在埃塞俄比亚开展的多中心前瞻性观察研究纳入168对乙型肝炎表面抗原阳性且HIV阴性的母婴,比较出生时接种乙型肝炎疫苗联合或不联合乙型肝炎免疫球蛋白(HBIg)对母婴传播的影响。9月龄时,联合HBIg组2/112(1.8%)婴儿HBsAg阳性,单用疫苗组2/23(8.7%),两者均未接种组8/33(24.2%),三组比较P=0.002。母体高病毒载量(>200,000 IU/ml;AOR 10.4;95%CI 1.2-92.1)和未接种出生剂量疫苗且未用HBIg(AOR 29.2;95%CI 4.0-211.3)是母婴传播的独立预测因素。

要点

  • 出生剂量乙型肝炎疫苗联合或不联合HBIg可显著降低埃塞俄比亚HBV母婴传播风险。
  • 9月龄HBsAg阳性率:联合HBIg组1.8%(2/112)、单用疫苗组8.7%(2/23)、均未接种组24.2%(8/33),P=0.002。
  • 母体病毒载量>200,000 IU/ml(AOR 10.4;95%CI 1.2-92.1)和未接种出生剂量疫苗且未用HBIg(AOR 29.2;95%CI 4.0-211.3)为独立预测因素。

核心结论

  • 出生剂量乙型肝炎疫苗联合或不联合HBIg可显著降低埃塞俄比亚HBV母婴传播风险。
  • 作者认为提高出生剂量乙型肝炎疫苗覆盖率应作为紧急优先事项。

研究设计与样本

  • 多中心、前瞻性、观察性研究,2019年1月至2021年5月在埃塞俄比亚开展。
  • 纳入HBsAg阳性且HIV阴性的孕妇及其婴儿,孕妇在常规产前保健和/或分娩时筛查HBsAg和HIV。
  • 推荐出生剂量乙型肝炎疫苗和HBIg但非国家政策,所有婴儿在6、10、14周龄接种五价乙型肝炎疫苗。
  • 290名HBsAg阳性孕妇中168对母婴完成9月龄随访并纳入分析。
  • 婴儿9月龄检测HBsAg,阳性结果视为母婴传播证据。

主要发现

  • 9月龄HBsAg阳性率:出生时接种疫苗联合HBIg组2/112(1.8%),单用出生剂量疫苗组2/23(8.7%),两者均未接种组8/33(24.2%),三组比较P=0.002。
  • 母体病毒载量>200,000 IU/ml与母婴传播独立相关(AOR 10.4;95%CI 1.2-92.1)。
  • 未接种出生剂量HBV疫苗且未用HBIg与母婴传播独立相关(AOR 29.2;95%CI 4.0-211.3)。

临床怎么用

  • 作者认为提高出生剂量乙型肝炎疫苗覆盖率应作为紧急优先事项。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Historically, mother-to-child transmission (MTCT) of hepatitis B virus (HBV) was considered uncommon in Africa, leading to a reluctant attitude to birth-dose HBV vaccination on the continent. As a randomized trial would be unethical, real-life data are needed to assess the effect of HBV birth-dose vaccine in Africa. METHODS: A multicenter, prospective, observational study of hepatitis B surface antigen (HBsAg)-positive pregnant women and their infants was carried out in Ethiopia, from January 2019 to May 2021. Pregnant women were screened for HBsAg and HIV as part of routine antenatal care and/or delivery, and HBsAg-positive HIV-negative pregnant women were included in the study. HBV birth-dose vaccine and hepatitis B immunoglobulin (HBIg) were recommended but not all newborns received it as it was not national policy. All infants, however, received the pentavalent HBV vaccine at 6, 10, and 14 weeks of age. Vaccination status was confirmed from delivery ward charts and infant vaccination certificates. Infants were tested for HBsAg at 9 months of age and a positive result was taken as evidence of MTCT. FINDINGS: Of 290 HBsAg-positive pregnant women, 168 mother/infant pairs returned for their 9-month follow-up visit and were included in this analysis. Two of 112 (1.8 %) infants who received birth-dose vaccine with HBIg, and 2 of 23 (8.7 %) who received birth-dose vaccine alone were HBsAg positive at nine months of age, compared to 8 of 33 (24.2 %) who received neither vaccine nor HBIg at birth (p = 0.002). High maternal viral load (>200,000 IU/ml; adjusted odds ratio [AOR] 10.4; 95 % confidence interval [CI] 1.2-92.1) and not receiving HBV birth-dose vaccine nor HBIg (AOR 29.2; 95 % CI 4.0-211.3) were independent predictors of MTCT. INTERPRETATION: Birth-dose HBV vaccine with or without HBIg significantly reduced the risk of MTCT of HBV in Ethiopia. Improved coverage of birth-dose HBV vaccine should be an urgent priority.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Arefaine M, Johannessen A, Teklehaymanot T, et al. A prospective, multicenter study of hepatitis B birth-dose vaccine with or without hepatitis B immunoglobulin in preventing mother-to-child transmission of hepatitis B virus in Ethiopia. Vaccine. 2024. PMID: 39426287. doi:10.1016/j.vaccine.2024.126461

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。